Swiss drugmaker Roche is seeing falling sales in Europe, stable sales in the United States and double-digit growth in Asia, its Chief Executive said in an interview with a Swiss newspaper on Sunday.
Asked about the company's performance in 2011, Severin Schwan told SonntagsZeitung: "While sales are stable in the US, we see falling numbers in Europe. In Asia, we see double-digit growth, especially in China where the growth rate is significantly above 30 percent."
The pharma industry is grappling with pricing pressures as cash-strapped governments cut back on healthcare spending.
But Schwan said he was confident on Roche's perspectives. "(Chairman Franz Humer) and I are both very confident that Roche can outperform the market in the mid and long term."
Comments
Comments are closed for this article.